Oncology

The CAR T-cell therapy tisagenlecleucel (Kymriah) achieved an overall response rate of 53.1% in adult patients with relapsed/refractory diffuse large B-cell lymphoma.

Treatment with the BCMA-directed CAR T-cell therapy bb2121 induced complete remissions for 56% of patients with relapsed/refractory multiple myeloma.

The FDA has granted a priority review to a biologics license application for mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.

Dan T. Vogl, MD, highlights the potential with CAR T-cell therapy in the multiple myeloma paradigm.

An early-stage trial in pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) has found that modifying the chimeric antigen receptor (CAR) T cells to target the CD22 receptor achieved remission.

The FDA has granted the the anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy bb2121 a breakthrough therapy designation for previously treated patients with relapsed/refractory multiple myeloma.

Sarah K. Tasian, MD, discusses the success of CAR T-cell therapy, as well as novel agents and immunotherapies that appear promising in the treatment of children with leukemia.

Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the approval of a chimeric antigen receptor (CAR) T-cell therapy in pediatric acute lymphoblastic leukemia.

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, comments on the toxicities associated with using chimeric antigen receptor (CAR) T-cell therapy in patients with leukemia.

The FDA has approved brentuximab vedotin (Adcetris) as a treatment for patients with cutaneous T-cell lymphoma who have received prior systemic therapy.

CD19 CAR T cells are highly effective in high-risk patients with chronic lymphocytic leukemia who have failed to respond to treatment with ibrutinib, a Bruton's tyrosine kinase inhibitor, according to a new study.

Maintenance therapy with lenalidomide following autologous stem-cell transplantation conferred a survival benefit for patients with newly diagnosed multiple myeloma.

Chimeric antigen receptor T-cell therapy may soon hit the market, and numerous cancer care centers are poised to offer this for what may be the first FDA-approved indication: relapsed/refractory B-cell acute lymphoblastic leukemia.

A look at some of the major developments in the chimeric antigen receptor T (CAR-T) cell space.

Novartis’ just-approved chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel is going to be introduced on the market at a price of $475,000 for a single infusion, an amount that is within the range anticipated by oncologists.

Chimeric antigen receptor (CAR)-T cells can re-expand in a lymphoma patient months after the initial infusion and can also be active against the patient’s cancer, according to a new study.

Shaji Kumar, MD, discusses his ixazomib maintenance trial, the latest FDA activity in myeloma, and the potential of chimeric antigen receptor (CAR) T-cell therapy in the field of myeloma.

A study on long-term remission of diffuse large B-cell lymphoma (DLBCL) shows that Kite Pharma’s anti-CD19 chimeric antigen receptor-T (CAR-T) cell treatment resulted in remission for up to 56 months.

Novartis’ chimeric antigen receptor T-cell (CAR-T) therapy for treating pediatric leukemia is on the cusp of being the first FDA-approved gene therapy, which will lead to new developments and utilizations of CAR-T therapy for treating other advanced blood cancers.

Results from the phase III Myeloma XI study showed that patients with myeloma had deeper responses after induction and after allo-stem cell transplantation with outpatient-delivered quadruplet therapy than with sequential immunomodulatory triplet combinations.

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses CAR T-cell therapy in multiple myeloma.

Sarah Rutherford, MD, discusses rare DLBCL subtypes, ongoing research to improve outcomes for these patient populations, and the potential role of CAR T-cell therapy.

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma.

Early results from a Chinese study showed that 33 of 35 patients (94%) with relapsed or refractory multiple myeloma experienced clinical remission after treatment with chimeric antigen receptor T cells targeting B-cell maturation protein.

Craig Portell, MD, of the University of Virginia Health System, highlights some of the latest and most exciting treatments in non-Hodgkin's lymphoma, including CAR-T therapies and targeted therapies such as venetoclax.

Ruben Niesvizky, MD, discusses some of the exciting advances, the potential of chimeric antigen receptor T-cell therapy, and emerging combination regimens on the horizon in multiple myeloma.

John P. Leonard, MD, associate dean of Clinical Research, interim chair of the Department of Medicine, Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the emergence and potential of chimeric antigen receptor (CAR) T-cell therapy across hematologic malignancies.

Stephen M. Ansell, MD, PhD, discusses the potential of immunotherapy agents in lymphoma, ongoing clinical trials, and where this blends in with chimeric antigen receptor (CAR) T-cell therapy.

The FDA has granted a breakthrough therapy designation to tisagenlecleucel-T (CTL019) for use as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma after the failure of at least 2 prior therapies.

CAR-T cell treatment can have a number of side effects, with the most serious being cytokine release syndrome, according to David L. Porter, MD, of the University of Pennsylvania Health System. However, there are some promising therapies like interleukin-6 blockers that can reverse this reaction.